Business Standard

Zydus settles patent litigation related to seizure drug with US-based firm

As per the pact, Zydus to begin selling a generic version of Supernus' Trokendi XR on Jan 1, 2023

Zydus settles patent litigation related to seizure drug with US-based firm
Premium

BS B2B Bureau Ahmedabad
Zydus Cadila has settled a patent litigation related to the US-based Supernus Pharmaceuticals’ Trokendi XR (extended-release topiramate) capsules. “Cadila Healthcare Limited and its subsidiary Zydus Pharmaceutical (USA) Inc have finalised an agreement Supernus Pharmaceuticals to settle all outstanding patent litigation related to Trokendi XR (extended-release topiramate) capsules,” said Zydus in a press release.

Two sides were involved in a patent litigation regarding Zydus’ abbreviated new drug application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR capsules.

The settlement agreement permits Zydus to begin selling a generic version of Trokendi XR on January 1, 2023, or earlier under certain circumstances.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in